¿ Affymetrix Inc., of Santa Clara, Calif., and InphoGene BioCom Inc., of Vancouver, British Columbia, said that InphoGene will use Affymetrix's GeneChip probe arrays to build an Internet-based commercial reference source for gene expression information relating to cardiopulmonary disease. InphoGene will market its databases broadly to pharmaceutical and biotechnology companies to assist in drug discovery activities. InphoGene will pay Affymetrix annual subscription fees, purchase probe arrays, related instrumentation and software. After certain milestones have been achieved, it will pay royalties to Affymetrix on database subscription fees.

¿ Amersham Pharmacia Biotech, of Uppsala, Sweden, has acquired the worldwide exclusive distribution rights to Inactine technology from V.I. Technologies Inc., of Melville, N.Y., for biopharmaceuticals, plasma derivatives and transgenic products. Inactine inactivates viruses in all classes of viruses known to infect blood. Terms of the deal were not disclosed.

¿ Ariad Pharmaceuticals Inc., of Cambridge, Mass., reiterated the call notice for redemption of its common stock purchase warrants and the general procedures for exercising the remaining warrants prior to their expiration at 5 p.m. today, April 26. The call date for the company to redeem the warrants is April 27. Upon exercise and payment of $8.40, warrant holders will receive one freely tradable share of Ariad common stock for each warrant.

¿ Biopure Corp., of Cambridge, Mass., said it has extended the shelf life of its veterinary oxygen therapeutic, Oxyglobin, from 24 months to 36 months, based on data showing the product remains stable over a broad temperature range for at least three years. The longer shelf life also extends the original expiration date of those units already on the market. The FDA cleared the product for marketing in January 1998 for the treatment of canine anemia.

¿ Boston Life Sciences Inc., of Boston, said it submitted the Altropane-SPECT scans from the company's Phase II trial to a panel of outside nuclear medicine specialists who then interpreted the scans in a "blinded" manner. Results revealed a 98 percent overall accuracy in identifying whether a particular subject had Parkinson's disease.

¿ BSD Medical Corp., of Salt Lake City, said it received approval from the FDA for Phase I/II clinical studies of hyperthermia in combination with liposome encapsulated doxorubicin for the treatment of ovarian cancer. Duke University will conduct the studies, and hyperthermia will be administered using BSD Medical's advanced BSD-2000 deep regional phased array hyperthermia system. Doxil, the FDA-approved liposomes that will be used for the study, are produced by Alza Pharmaceuticals, of Palo Alto, Calif.

¿ Centaur Pharmaceuticals Inc., of Sunnyvale, Calif., completed enrollment in its U.S. Phase IIa trial in patients with AIDS dementia complex (ADC). The trial is being conducted in 64 HIV-infected patients with cognitive and motor impairment, with the objective of evaluating the tolerability, safety and preliminary efficacy of Centaur's ADC drug candidate, CPI-1189, following once-daily dosing to HIV-infected patients over several weeks. The company expects the study results will be available later this year.

¿ Charles River Laboratories Holdings Inc., of Wilmington, Mass., said it filed a registration statement with the SEC for a proposed initial public offering of its common stock. The company listed a proposed maximum aggregate offering amount of $230 million. Charles River is a provider of research tools and integrated support services that enable drug discovery and development.

¿ Clinical Micro Sensors Inc., of Pasadena, Calif., completed a clinical study showing its eSensor biochip technology matches conventional DNA testing of genetic mutations linked to hereditary hemochromatosis. In the study, eSensor technology analyzed 56 patient samples with genetic profiles unknown to the company, and with 10 known profiles. The technology successfully identified the status of all 66 patient samples. These samples included mutations coding for the C282Y and H63D amino acid changes, which are the most common defects responsible for hereditary hemochromatosis.

¿ Digital Gene Technologies Inc., of La Jolla, Calif., said scientists at the Mayo Foundation for Medical Education and Research will use DGT's patented TOGA gene expression profiling technology to investigate the role of the transcription factor ER81 in the formation of a variety of different tumors, including those associated with breast and ovarian cancer, as well as Ewing's sarcoma.

¿ Gene Logic Inc., of Gaithersburg, Md., launched its GeneExpress 2000 database suite, the next generation of its GeneExpress gene expression database product. The GeneExpress 2000 database is a massive reference set of gene expression information across a broad range of normal and diseased human tissues, experimental animals and disease models and cell lines.

¿ Genentech Inc., of South San Francisco, said its new state-of-the-art manufacturing facility in Vacaville, Calif., has passed regulatory inspection by the FDA and all validation and production lot data have been found to be acceptable for the production of Herceptin, the company's breast cancer drug. The company began construction of the facility in 1995 and it became fully operational in 1999.

¿ International Biotechnology Trust, of London, said it invested $10 million in Delsys Pharmaceuticals Inc., of Princeton, N.J. The trust was the lead investor in the $26 million round of financing. (See BioWorld Today, April 25, 2000, p. 1.)

¿ LJL BioSystems Inc., of Sunnyvale, Calif., said it introduced and initiated commercial shipments of its first-generation High Efficiency Fluorescence Polarization assay for cyclic AMP (cAMP) to be used in cell-based analysis. The assay can be used to monitor responses of G protein-coupled receptors to drug candidates by measuring levels of intracellular cAMP to determine adenylate cyclase activity.

¿ Teva Marion Partners, of Kansas City, Kansas, is conducting the first global study for an oral multiple sclerosis drug therapy in order to determine if an oral formulation of Copaxone (glatiramer acetate for injection) is efficacious and safe for the treatment of relapsing-remitting MS. Called the Coral Study, the Phase III study will span five continents and 18 countries and involve 1,300 patients, including 600 to 700 Americans.

¿ Xanthon Inc., of Research Triangle Park, N.C., leased a 14,000-square-foot manufacturing facility and is up-fitting it in order to meet its initial product manufacturing requirement, beginning with its beta-site product evaluations scheduled for the fall.

No Comments